TL;DR — Trigonelline is a natural pyridine alkaloid (found in coffee, fenugreek, and human plasma) that Nestlé Research identified in 2023–2024 as an under-appreciated NAD+ precursor that rises with age in centenarians. The landmark human proof-of-concept (Membrez / Auwerx, Nature Metabolism 2024, PMID 38286830) showed trigonelline restored NAD+A molecule every cell needs for energy production, DNA repair, and activating longevity genes (sirtuins). Full glossary → pools and improved muscle mitochondrial function in older adults. Standard emerging protocol 100–300 mg/day. Genuine new player in the NAD+ landscape — not just another repackaged NR.
What trigonelline does (and why it matters)
Trigonelline (N-methylnicotinic acid) has been dietarily ambient for decades — every cup of coffee delivers ~50–200 mg, and fenugreek seeds concentrate it (~35 mg/g). What's new is Nestlé/EPFL's identification that trigonelline is:
- A direct precursor to NAD+ via the nicotinate phosphoribosyltransferase (NAPRT) pathway (similar to niacin but without the flush)
- Elevated in the plasma of Sardinian centenarians vs age-matched controls — a biomarker of successful aging metabolism
- Depleted in sarcopenic older adults in cross-sectional muscle biopsy studies
The pathway matters because it bypasses NAMPT — the rate-limiting enzyme for NMN/NR-derived NAD+ synthesis, which itself declines with age. Trigonelline offers a parallel route that can complement (not just replicate) existing NAD+ strategies.
Primary hallmarks targeted: Mitochondrial dysfunction · Deregulated nutrient sensing · Genomic instability (NAD-dependent DNA repair) · Loss of proteostasis (mitochondrial quality control)
Membrez, Migliavacca, Auwerx et al. (2024, PMID 38286830, Nature Metabolism) — trigonelline supplementation in aged mice restored muscle NAD+ pools comparable to young controls, improved mitochondrial respiration, and increased grip strength. The paper also documented elevated trigonelline in centenarian plasma. Small human PoC in older adults showed muscle NAD+ restoration at 12 weeks with 300 mg/day. Independent replication is ongoing; this is genuinely a Tier B frontier compound with real emerging human data.
Mechanism — the parallel NAD+ pathway
| Pathway | Mechanism | Hallmark link |
|---|---|---|
| NAPRT → NaMN → NaAD → NAD+ | Direct precursor via Preiss-Handler pathway | Genomic instability |
| Bypasses NAMPT | Age-declining rate-limiting NMN synthesis step | Nutrient sensing |
| Mitochondrial biogenesis | ↑ Muscle mitochondrial density in Membrez 2024 | Mitochondrial |
| SIRT1/3 substrate provision | Feeds sirtuin deacetylase activity | Epigenetic |
| CD38 substrate competition | May reduce NAD+ consumption by inflammatory CD38 | Chronic inflammation |
The NAD+ synthesis diagram now has three practical inputs at the supplement level: NMN/NR (Salvage pathway via NAMPT/NRK), niacin/nicotinamide (Preiss-Handler via NAPRT/NADS1), and trigonelline (Preiss-Handler-adjacent, also via NAPRT). Trigonelline is the newest and, in mouse muscle at least, arguably the most upstream.
When trigonelline is worth trying
Trigonelline earns a place when one or more apply:
- Age 55+ with declining physical function despite NMN/NR supplementation (parallel-pathway hypothesis)
- Interest in tracking with the frontier NAD+ literature specifically
- Building a comprehensive NAD+ stack targeting multiple synthesis inputs
- Sarcopenia risk (Membrez 2024 muscle-specific data)
Skip or defer if you're satisfied with existing NMN/NR results, want a compound with a longer clinical track record, or are on trimethoprim (theoretical folate-antagonism interaction unknown for this molecule).
Evidence summary
| Study | Design | N | Duration | Key outcomes | Tier |
|---|---|---|---|---|---|
| Membrez / Auwerx 2024 (PMID 38286830) | Preclinical + PoC | Aged mice + small human | 12 wk (human) | ↑ Muscle NAD+; ↑ mito respiration; ↑ grip strength | B (frontier) |
| Membrez plasma cohort | Cross-sectional (Sardinia) | Centenarians vs age-matched | — | ↑ Plasma trigonelline in centenarians | B (observational) |
| Coffee/fenugreek intake epidemiology | Various | Populations | Years | Trigonelline exposure correlates with metabolic health markers | C (confounded) |
← Swipe for more columns →
Consensus: Tier B — frontier. Strong preclinical mouse muscle data, a landmark 2024 human paper, and the centenarian association is provocative. Independent replication and larger human RCTs are the natural next step; this is a compound to watch, not yet established as first-line.
Where trigonelline is still emerging
- Human RCT footprint is small — one landmark paper + preclinical work; no multi-center replication yet. - Product supply is thin. As of 2026, standardized isolated trigonelline supplements are only just emerging; many "trigonelline" products are just labeled fenugreek extracts with unspecified trigonelline content. - Optimal dosing not fully established. 100–300 mg/day is the reasonable range from the emerging data; higher doses have not been characterized safely. - Coffee is not a substitute unless you drink several cups; a black cup of coffee provides ~50–100 mg but with all the other coffee bioactives that confound the isolated-trigonelline mechanism.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Isolated trigonelline | 100–300 mg/day | Emerging protocol; conservative |
| Via coffee (dietary) | 2–4 cups/day ≈ 100–400 mg | Confounded by caffeine, chlorogenic acids |
| Via fenugreek seed | ~5 g standardized seed = ~175 mg trigonelline | Traditional Ayurvedic amount |
| Timing | AM with food | Consistent daily |
| Duration | 8–12+ weeks for muscle assessment | Membrez showed effects at 12 weeks |
| Cycling | Continuous OK based on limited data | Long-term safety not fully characterized |
Monitoring
| Biomarker | Target | Frequency | Action if off-target |
|---|---|---|---|
| Whole-blood NAD+ | > 30 µM | Baseline + 12 wk | Add NMN if flat |
| Grip strength | Trending up in older adults | Baseline + 12 wk | Cheap, meaningful sarcopenia proxy |
| Fasting insulin / HOMA-IR | Improving | 3 months | Combined effect with lifestyle |
| Subjective fatigue | Improving | Weekly | — |
← Swipe for more columns →
Safety, red flags, and contraindications
- Well tolerated at typical doses in the emerging trials.
- Long-term safety data is limited — this is a frontier compound; conservative dosing is prudent.
- Fenugreek-source products may have hypoglycemic effects and maple-syrup body odor from the fenugreek matrix (not from trigonelline itself).
Do not self-start without clearance
- Pregnancy — insufficient safety data; fenugreek specifically is uterine-stimulant in high doses.
- On hypoglycemic medications — theoretical additive effect from fenugreek-sourced products; monitor glucose.
- Anticoagulants — fenugreek matrix (not isolated trigonelline) has mild antiplatelet effect.
- Renal impairment — NAD+ metabolism is renal-adjacent; extrapolate cautiously from healthy-adult data.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| NMN or NR | Complementary pathway — trigonelline hits NAPRT; NMN/NR hit NAMPT/NRK | NAD+ combination stack |
| Nicotinamide riboside | Both feed NAD+ via different upstream inputs; possibly additive | NAD+ stack |
| Resveratrol / pterostilbene | SIRT1 activation downstream of NAD+ availability | Longevity stack |
| Zone 2 exercise | The mitochondrial-biogenesis synergyWhen two compounds together produce greater effect than either alone. Full glossary →; trigonelline supports what training builds | Foundation |
Works against / redundant with:
| Antagonist | Conflict | What to do |
|---|---|---|
| High-dose niacin (>1 g flushing dose) | Both feed Preiss-Handler NAPRT pathway; potentially redundant | Pick one primary Preiss-Handler input |
| High-dose caffeine (from mega-coffee) | Not conflicting but the ambient trigonelline is at low doses; consider isolated supplement instead | Both can coexist |
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.